A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients.
Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIV-positive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication.
Infectious Diseases Unit, G.B. Rossi Hospital, Via piazzale L. Scuro 10, Verona, Italy. lanzafame.massimiliano@gmail.com
Massimiliano
M
Lanzafame
Stefano
S
Bonora
Emanuela
E
Lattuada
Andrea
A
Calcagno
Sandro
S
Vento
D000328:Adult; D018791:CD4 Lymphocyte Count; D000069454:Darunavir; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome; D019562:Viral Load
D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir